medmix AG (MEDX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, medmix AG (MEDX) has a cash flow conversion efficiency ratio of 0.086x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CHF37.40 Million ≈ $47.28 Million USD) by net assets (CHF432.80 Million ≈ $547.18 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is medmix AG's balance sheet to measure how much of total assets are equity-financed.
medmix AG - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how medmix AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of medmix AG to evaluate the quality of earnings relative to operating cash generation.
medmix AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of medmix AG ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
INPAQ Technology Co Ltd
TWO:6284
|
0.036x |
|
Gourmet Master Co Ltd
TW:2723
|
0.067x |
|
Inner Mongolia North Hauler Joint Stock Co Ltd
SHG:600262
|
0.119x |
|
Eche Izquierdo
SN:EISA
|
0.071x |
|
Third Point Investors Limited
LSE:TPOU
|
-0.004x |
|
Dufu Tech Corp Bhd
KLSE:7233
|
-0.004x |
|
Boston Omaha Corp
NYSE:BOC
|
0.011x |
|
Beijing Century Real Tech
SHE:300150
|
0.050x |
Annual Cash Flow Conversion Efficiency for medmix AG (2018–2025)
The table below shows the annual cash flow conversion efficiency of medmix AG from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see MEDX company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CHF432.80 Million ≈ $547.18 Million |
CHF67.80 Million ≈ $85.72 Million |
0.157x | -19.19% |
| 2024-12-31 | CHF446.70 Million ≈ $564.75 Million |
CHF86.60 Million ≈ $109.49 Million |
0.194x | +63.94% |
| 2023-12-31 | CHF474.40 Million ≈ $599.77 Million |
CHF56.10 Million ≈ $70.93 Million |
0.118x | +25.41% |
| 2022-12-31 | CHF504.80 Million ≈ $638.20 Million |
CHF47.60 Million ≈ $60.18 Million |
0.094x | -42.33% |
| 2021-12-31 | CHF533.90 Million ≈ $674.99 Million |
CHF87.30 Million ≈ $110.37 Million |
0.164x | +7.74% |
| 2020-12-31 | CHF333.40 Million ≈ $421.51 Million |
CHF50.60 Million ≈ $63.97 Million |
0.152x | -49.73% |
| 2019-12-31 | CHF295.10 Million ≈ $373.09 Million |
CHF89.10 Million ≈ $112.65 Million |
0.302x | +8.88% |
| 2018-12-31 | CHF339.70 Million ≈ $429.47 Million |
CHF94.20 Million ≈ $119.09 Million |
0.277x | -- |
About medmix AG
medmix AG designs, produces, and sells high-precision devices and services in Switzerland and internationally. It operates through the Healthcare, and Consumer and Industrial segments. The company offers dispensers, cartridges, mixers, tips, syringes, pen, and auto injectors for delivery of dental materials; delivery devices and mixing for bone repair and tissue treatment, which are used for pros… Read more